Showing 2061-2070 of 5643 results for "".
- Researchers Found a Way to Reactivate Dormant Cells in the Retinahttps://modernod.com/news/researchers-found-a-way-to-reactivate-dormant-cells-in-the-retina/2481610/There's new hope for potentially restoring vision in patients suffering from degenerative retinal disease, thanks to work by researchers at Université de Montréal (UdeM). Published this week in Proceedings of the National Academy of Sciences, the research was
- Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCEDhttps://modernod.com/news/kala-pharmaceuticals-announces-fda-acceptance-of-ind-application-for-kpi-012-for-the-treatment-of-pced/2481312/Kala Pharmaceuticals announced that the FDA has accepted an investigational new drug (IND) application for the company’s lead product candidate, KPI-012, a human mesenchymal stem cell secretome (MSC-S), initially in development for the treatment of persistent corneal epithelial de
- Rayner Establishes Direct Presence in Francehttps://modernod.com/news/rayner-establishes-direct-presence-in-france/2480956/Rayner announced its direct entry into the French cataract and refractive market. Based out of Lille in the Hauts-de-France region, Rayner has a growing team of ophthalmic specialist area managers focussed on delivering service and support. Through this team, French ophthalmologist
- Oxurion Appoints Tom Graney, CFA, as Chief Executive Officerhttps://modernod.com/news/oxurion-appoints-tom-graney-cfa-as-chief-executive-officer/2479215/Oxurion NV announced in a planned succession, the promotion of Tom Graney, CFA, from Chief Financial Officer (CFO) to Chief Executive Officer (CEO) of the company. He takes over from Patrik De Haes, MD, who after 14 years as CEO has decided to move away from day-to-day management
- Heine Announces Launch of Omega 600 Lightweight Indirect Ophthalmoscopehttps://modernod.com/news/heine-announces-launch-of-new-omega-600-lightweight-indirect-ophthalmoscope/2478842/Heine has launched its newest indirect ophthalmoscope, the Omega 600. The Omega 600 includes a new design that makes it the lightest high-end indirect on the market courtesy of a new ultralight battery, according to Heine. Other new features are Heine’s visionBOOST technology, which is des
- Preliminary Results From Aldeyra’s Phase 3 Tranquility Trial Offer Promise for Patients With Dry Eye Syndrome, Says GlobalDatahttps://modernod.com/news/preliminary-results-from-aldeyras-phase-3-tranquility-trial-offer-promise-for-patients-with-dry-eye-syndrome-says-globaldata/2478786/Aldeyra Therapeutics recently announced topline results from the run-in cohort of the phase 3 trial evaluating reproxalap 0.25% for patients with dry eye syndrome (DES). The positive impact of the therapy on endpoints, such as ocular dryness, discomfort and Schirmer’s test, although preliminary,
- Wize Pharma Announces Positive Topline Results in Phase 4 Study of LO2A for Dry Eye in Patients with Sjögren’s Syndromehttps://modernod.com/news/wize-pharma-announces-positive-topline-results-in-phase-4-study-of-lo2a-for-dry-eye-in-patients-with-sjogrens-syndrome/2478529/Wize Pharma reported topline results from its phase 4 clinical trial of its in-license eye drop formula, LO2A, for the symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren’s syndrome. The randomized, double-masked comparative study evaluated LO2A versus Alcon̵
- Aurinia Pharmaceuticals’ Dry Eye Drug Candidate Does Not Meet Primary Endpointhttps://modernod.com/news/aurinia-announces-outcome-of-audrey-clinical-trial-in-dry-eye-syndrome/2478487/Aurinia Pharmaceuticals announced topline data from the phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). The trial did not achieve statistical significance on its primary endpoint of a 10 mm or greater improvem
- Oxurion NV to Provide Business and Clinical Update at AAO and OIS Meetings in San Franciscohttps://modernod.com/news/oxurion-nv-to-provide-business-and-clinical-update-at-aao-and-ois-meetings-in-san-francisco/2476969/Oxurion NV announces that the company will be providing a business and clinical update at the American Academy of Ophthalmology’s annual meeting (AAO) and Ophthalmology Innovation Summit (OIS@AAO) in San Francisco. Patrik De Haes, MD, CEO of Oxurion will be presenting the company’s b
- Haag-Streit Announces the Launch of the Ellex Eye Prime in UKhttps://modernod.com/news/haag-streit-uk-announces-the-launch-of-the-ellex-eye-prime/2476912/Haag-Streit UK (HS-UK) has announced the launch of the Eye Prime diagnostic ultrasound system in the UK. The Eye Prime is the next-generation ultrasound solution from Ellex. It features the industry’s first and only “six-ring phased annular array technology,” delivering crisp, high-de